Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20060540
    Release date: 15 January 2008

    Promoter – Financial Intermediary

    Coloplast A/S

    Location

    Description

    The project concerns the promoter’s research, development and innovation (RDI) activities within its Ostomy Care, Urology/Continence Care and Wound and Skin Care divisions targeting novel innovative product platforms and product improvements. The promoter aims to half the time to market and more than double its pipeline value by 2011, mainly by reaping synergies between different business areas; the implementation of this strategy will impact the present project. The project will be implemented in the period 2008-2010.

    Objectives

    The project should strengthen the market position of a medium-sized EU-based niche player, operating in the segmented global market for medical care products and services.

    Sector(s)

    Proposed EIB finance (Approximate amount)

    EUR 60 million.

    Total cost (Approximate amount)

    EUR 160 million.

    Environmental aspects

    The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres etc. An EIA therefore is not required by EU Directive 97/11 as amended by Directive 2003/35. Compliance of R&D activities with relevant EU environmental legislation will be verified during appraisal.

    Procurement

    The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU directives on procurement.

    Status

    Signed - 22/12/2008

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Denmark Industry